SCHEMBL3763

SCHEMBL3763

O=c1cc[nH]c(=O)n1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7650218 0.98 TP53 (0.33) —
SCHEMBL27572393 0.98 BRD4 (0.31) —
Water SCHEMBL28246131 0.98 BRD4 (0.31) —
Ammonia Solution, Strong SCHEMBL28255127 0.98 BRD4 (0.31) —
Fluoride SCHEMBL27679532 0.98 BRD4 (0.31) —
Hydrochloric Acid SCHEMBL27558760 0.98 KMT2A (0.33) —
Benzene SCHEMBL26606838 0.95 MAPK8 (0.36) —
Hydrochloric Acid SCHEMBL28839646 0.95 BRD4 (0.31) —
Water SCHEMBL27758775 0.95 BRD4 (0.31) —
Hno SCHEMBL27940461 0.95 BRD4 (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 133095 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747263-A1 LIPID NANOPARTICLES AND USES THEREOF University of Connecticut (US) 2026-05-27 — — EP claimed
CN-122075677-A GM-CSF loaded tumor cell vaccine and application thereof in preventing and treating liver cancer — 2026-05-26 — — CN claimed
US-20260139321-A1 METHODS FOR SEQUENCING SAMPLES AQTUAL INC (US) 2026-05-21 — — US claimed
US-20260137678-A1 METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2026-05-21 — — US claimed
WO-2026102563-A1 DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF 深圳湾实验室坪山生物医药研发转化中心 2026-05-21 — — WO claimed
US-20260137700-A1 PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE SK BIOPHARMACEUTICALS CO LTD (KR) 2026-05-21 — — US claimed
WO-2026105121-A1 ANTICANCER FORMULATIONS AND USES THEREOF INTRAGEL THERAPEUTICS LTD. (IL) 2026-05-21 — — WO claimed
US-20260137674-A1 COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITOR INCYTE CORP (US) 2026-05-21 — — US claimed
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 — — EP claimed
CN-122056884-A Methods of treating pancreatic cancer 坎莫森特里克斯公司 2026-05-19 — — CN claimed
US-4671958-A Antibody conjugates for the delivery of compounds to target sites CYTOGEN CORPORATION (US) 1987-06-09 — — US claimed
EP-0213552-A2 Oily suspension for intrarectal infusion FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1987-03-11 — — EP claimed
CN-85104201-A From uridylic acid produce 5-fluoro-2 '-method of deoxyuridine — 1986-11-26 — — CN claimed
CN-85108855-A The preparation method of 1-(2-tetrahydrofuran base)-5 FU 5 fluorouracil — 1986-09-24 — — CN claimed
CN-85107905-A The preparation of uridine — 1986-07-16 — — CN claimed
US-4565806-A Composition and method for rational treatment of cancer SETAELAE KAI M E 1986-01-21 — — US claimed
EP-0120907-A1 PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY Aston Molecules Limited (GB) 1984-10-10 — — EP claimed
WO-1984001506-A1 PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY UNIV BIRMINGHAM (GB) 1984-04-26 — — WO claimed
EP-0010964-A1 Ravidomycin, process of preparation and pharmaceutical compositions containing same AYERST, MCKENNA AND HARRISON INC. (CA) 1980-05-14 — — EP claimed
US-3992208-A Photo-sensitive etchant and method for forming metal image using same FUJI PHOTO FILM CO., LTD. (JA) 1976-11-16 — — US claimed
Send feedback